Subscribe via RSS

Tag: pharmaceuticals

Equities
Drug maker United Laboratories sells $125 million of CBs
United Labs' renminbi-denominated convertible bond comes at attractive terms, but still falls below par.
By Anette Jönsson | 8 November 2011
Equities
Shanghai Pharma raises $2 billion from Hong Kong listing
China's second-biggest drug distributor prices its H-share offering below the mid-point, but at a modest 2.4% discount versus its A-shares.
By Anette Jönsson | 16 May 2011
M&A
Reckitt buys Paras for $726 million
As the year draws to a close, private-equity firm Actis orchestrates the sale of its portfolio company Paras Pharmaceuticals in India to Reckitt Benckiser for $726 million.
By Sameera Anand | 14 December 2010
M&A
Cardinal Health buys Yong Yu from Zuellig
US pharmaceutical distributor Cardinal Health agrees to pay $470 million for China’s largest pharmaceutical importer, Zuellig Pharma China, known locally as Yong Yu.
By Sameera Anand | 1 December 2010
Equities
Liansu raises $250 million, while WWTT withdraws IPO
The increasingly selective approach by investors also works in favour of Sino Biopharmaceutical which is able to raise $144 million from an upsized placement earlier this week.
By Lillian Liu | 18 June 2010
M&A
Charles River buys WuXi PharmaTech in $1.6 billion deal
Pharmaceutical research company Charles River pays $1.6 billion in cash and stock to acquire Chinese outsourcing company WuXi PharmaTech two-and-a-half years after its listing ...
By Sameera Anand | 27 April 2010
Equities
Massive demand for Sinopharm bodes well for IPO pipeline
The Chinese pharmaceutical distributor prices at the top to raise $1.13 billion after attracting $110 billion worth of orders. Separately, Digital China raises $49 million from ...
By Anette Jönsson | 17 September 2009
M&A
Japan's Taisho buys select Asian assets from Bristol-Myers
Japanese firm Taisho Pharmaceutical pays $310 million for six Asia-Pacific brands and the Indonesian business of Bristol-Myers, as it seeks to build its presence in the OTC ...
By Sameera Anand | 17 September 2009
Equities
Sinopharm sets price range for $1.13 billion IPO
The Chinese distributor of pharmaceutical products will be the first company to take orders for a Hong Kong listing after the summer and has set the price range at HK12.25 to ...
By Anette Jönsson | 4 September 2009
M&A
Japan's Hisamitsu to buy US Noven for $428 million
Hisamitsu becomes the fourth Japanese pharmaceutical company to announce a US acquisition in the recent past, as it makes a tender offer for transdermal and women's health ...
By Sameera Anand | 16 July 2009
M&A
Japan's Shionogi inks $1.4 billion US acquisition
The prescription drug firm buys specialised US company Sciele in the fourth Japanese outbound pharmaceutical deal in less than a year.
By Sameera Anand | 2 September 2008
Equities
United Laboratories prices Hong Kong IPO at the top
Institutional investors get 70% of the $105 million offering from the Chinese drug maker. Retail subscriptions are less overwhelming.
By Anette Jönsson | 11 June 2007
Equities
Chinese drug maker seeks Hong Kong listing
IPO investors will need to weigh up United Laboratories' strong structural growth potential and generous valuation against a regulated market with plenty of competition and ...
By Anette Jönsson | 29 May 2007
Equities
Simcere breaks negative trend for Chinese listings in the US
The pharmaceutical company trades up 5.5% after pricing its $226.5 million IPO at the top of the range.
By Anette Jönsson | 23 April 2007
Equities
Repeat Indian issuer brings $250 million CB
Sterling Biotech prices wide after demand is described as healthy but price sensitive.
By Anette Jönsson | 20 April 2007
Equities
Tongjitang prices US IPO 33% below initial price range
The Chinese medicine maker becomes the first Mainland company to cut the size of a US offering this year as the fall-out from the equity market correction broadens.
By Anette Jönsson | 19 March 2007
Equities
Chinese drug maker seeks NYSE listing
The company banks on an ageing Chinese population and higher urban wealth to drive growth of its key drug.
By Anette Jönsson | 1 March 2007
Equities
Orchid CB receives brutal treatment in the secondary market
A hefty increase in the deal size and concern about the use of proceeds push the bond price sharply below par.
By Anette Jönsson | 16 February 2007
Equities
Upsized CB for Indian drug maker
Orchid Chemicals raises $175 million to grow its portfolio of drugs. Conversion premium set at 30%.
By Anette Jönsson | 13 February 2007
Equities
Wuyi prices IPO at top end, Meadville in the upper half of the range
The first two Hong Kong IPOs of size this year raise $255 million between them. Retail demand remains strong, triggering full clawbacks on both deals.
By Anette Jönsson | 29 January 2007
1 2 | Next »
Tag Filters
acquisition actis america asia barclays capital bristolmyers squibb cardinal ccb international charles river china cicc citigroup convertible credit suisse deutche bank deutsche bank drugs electronics eric zwisler fabrics finance healthcare hsbc ipo jpmorgan merrill lynch morgan stanley nyse pcb pharma pipe placement private equity reckitt sciele sequoia shionogi sino biopharm sinopharm taisho textiles touch pad transdermal ubs united laboratories water supply wuxi wwtt yong yu zuellig
MOST READ
Polls
With Valentine's Day approaching, who would make the best match for Olympus?
   |   View results
Nikon
  23%
 
Sony
  15%
 
Panasonic
  19%
 
Fujifilm
  26%
 
Samsung
  17%
TOTAL VOTES: 47

 
View previous polls »
LATEST FROM AsianInvestor
Latest headlines from AsianInvestor
More from AsianInvestor »
WEBCASTS
On Demand Webcasts
View all webcasts »
Tables
Latest League Tables » Dealogic
DCM | ECM | M&A | Fees
Debt Pipeline »
Equity Pipeline »
Magazine
FinanceAsia Magazine
FinanceAsia
December 2011/January 2012